Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
HEALTH-RELATED QUALITY OF LIFE IN ITALIAN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPARED TO THE GENERAL POPULATION: GIMEMA PROPHECY STUDY	HEMASPHERE	2024
LEUKOCYTOSIS IN LOW-INTERMEDIATE RISK ACUTE PROMYELOCYTIC LEUKEMIA DURING ATRA-ATO INDUCTION THERAPY: A REAL-LIFE STUDY	HEMASPHERE	2024
MUTANT MYELOID GENE CATEGORY MAY PREDICT POOR RESPONSE TO JAK INHIBITORS IN PATIENTS WITH MYELOFIBROSIS	HEMASPHERE	2024
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)	EXPERT REVIEW OF HEMATOLOGY	2024
Case Report: Infectious prophylaxis in hematological malignancies	FRONTIERS IN ONCOLOGY	2023
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination	FRONTIERS IN ONCOLOGY	2023
Asciminib as a third line option in chronic myeloid leukemia	INTERNATIONAL JOURNAL OF HEMATOLOGY	2023
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	LEUKEMIA & LYMPHOMA	2023
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?	ANNALS OF HEMATOLOGY	2023
Systemic mastocytosis: 2023 update on diagnosis and management in adults	EXPERT OPINION ON EMERGING DRUGS	2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice	LEUKEMIA & LYMPHOMA	2023
Management of polycythemia vera: A survey of treatment patterns in Italy	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy	ADVANCES IN THERAPY	2023
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)	ANNALS OF HEMATOLOGY	2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome	CANCER	2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results	LEUKEMIA	2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials	ANNALS OF HEMATOLOGY	2023
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib	BLOOD CANCER JOURNAL	2023